Recarbrio यूरोपीय संघ - लिथुआनियाई - EMA (European Medicines Agency)

recarbrio

merck sharp & dohme b.v.  - imipenem monohidratas, cilastatin natrio, relebactam monohidratas - gram-neigiamų bakterijų infekcijos - carbapenems, antibacterials for systemic use, - recarbrio is indicated for:- treatment of hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap), in adults (see sections 4. 4 ir 5. - treatment of bacteraemia that occurs in association with, or is suspected to be associated with hap or vap, in adults. - treatment of infections due to aerobic gram-negative organisms in adults with limited treatment options (see sections 4. 2, 4. 4 ir 5. reikėtų atsižvelgti į oficialius nurodymus, kaip tinkamai naudoti antibakterinių veiksnių.

Dexmedetomidine Accord यूरोपीय संघ - लिथुआनियाई - EMA (European Medicines Agency)

dexmedetomidine accord

accord healthcare s.l.u. - dexmedetomidine - premedication - psicholeptikai - už sedacija suaugusiųjų icu (intensyvios slaugos skyrių) pacientams, kuriems reikalingas tam sedacija lygis ne giliau nei susijaudinimą, reaguodama į žodinis stimuliacija (atitinkamai į richmond, sujaudinimas-sedacija masto (rass) nuo 0 iki -3). už sedacija ne intubated suaugusiems pacientams prieš ir (arba) atliekant diagnostines ar chirurgines procedūras, reikalaujančias sedacija, i. procesinių/miega, sedacija.

Tigecycline Accord यूरोपीय संघ - लिथुआनियाई - EMA (European Medicines Agency)

tigecycline accord

accord healthcare s.l.u. - tigecycline - soft tissue infections; intraabdominal infections; bacterial infections; skin diseases, infectious - antibacterials sisteminio naudojimo, - tygecycline accord yra nurodyta suaugusiesiems ir vaikams nuo amžiaus aštuonerių metų gydyti šias infekcijas (žr. skirsnius 4. 4 ir 5. 1):komplikuotos odos ir minkštųjų audinių infekcijas (cssti), išskyrus diabetinės pėdos infekcijos (žr. skyrių 4. 4)sudėtinga vidinės pilvo infekcijos (ciai)tygecycline sutarimu turėtų būti naudojami tik tais atvejais, kai kiti alternatyvūs antibiotikai netinka (žr. skirsnius 4. 4, 4. 8 ir 5. reikėtų atsižvelgti į oficialius nurodymus, kaip tinkamai naudoti antibakterinių veiksnių.

MenQuadfi यूरोपीय संघ - लिथुआनियाई - EMA (European Medicines Agency)

menquadfi

sanofi pasteur - neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid - meningitas, meningokokas - vakcinos - menquadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y. the use of this vaccine should be in accordance with available official recommendations.

Supemtek यूरोपीय संघ - लिथुआनियाई - EMA (European Medicines Agency)

supemtek

sanofi pasteur - influenza a virus subtype h1n1 haemagglutinin, recombinant, influenza a virus subtype h3n2 haemagglutinin, recombinant, influenza b virus victoria lineage haemagglutinin, recombinant, influenza b virus yamagata lineage haemagglutinin, recombinant - gripas, žmogus - vakcinos - supemtek is indicated for active immunization for the prevention of influenza disease in adults. supemtek should be used in accordance with official recommendations.

Retsevmo यूरोपीय संघ - लिथुआनियाई - EMA (European Medicines Agency)

retsevmo

eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - antinavikiniai vaistai - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.

Kesimpta यूरोपीय संघ - लिथुआनियाई - EMA (European Medicines Agency)

kesimpta

novartis ireland ltd - ofatumumab - išsėtinė sklerozė, grįžtamoji-pervedimo - immunosuppressant - kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features (see section 5.

Enspryng यूरोपीय संघ - लिथुआनियाई - EMA (European Medicines Agency)

enspryng

roche registration gmbh - satralizumab - neuromyelitis optica - imunosupresantai - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

Abiraterone Mylan यूरोपीय संघ - लिथुआनियाई - EMA (European Medicines Agency)

abiraterone mylan

mylan ireland limited - abiraterono acetatas - prostatos navikai - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Abiraterone Krka यूरोपीय संघ - लिथुआनियाई - EMA (European Medicines Agency)

abiraterone krka

krka, d.d., novo mesto - abiraterono acetatas - prostatos navikai - endokrininė terapija - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.